Article "Il sole 24 ore": nemorubicin. It is the tale of a molecule named most valuable ally in the fight against cancer, the result of research of Nerviano Medical Sciences. In practice, the largest Italian company (and one of the most significant in Europe) in pharmaceutical research and development of oncology. In these days - let's not forget - the region of Lombardy, through its research institutes, is about to become the majority shareholder of the structure.
Also, the nemorubicin, one of the leading products of the assets of Nerviano, registered about 15 years ago as Pfizer, the product has already been deployed in the European market but unknown in the Far East.
The molecule enters phase tests on humans in Asia, once demonstrated activity in experimental models of cancer in vitro and in vivo, will start clinical development in China, thanks to a pre-agreement signed between nerve and 'Chinese pharmaceutical company to Guizhoi Yibai limited.
The agreement provides for the payment of two million down payment, another three at the end of clinical trials in China and, when fully implemented, 3% royalties for Nerviano the final product.
If everything will spin the right way, will be a Trojan horse to convey the Italian technology in a market long, and in some ways back, at least in some areas of research. This also explains the interest of the Chinese towards our country and, in particular, of our business-model.
Baielli Luciano, CEO of Nerviano Medical Sciences, has confidence in this strategy "to help open the Chinese market, after all - he adds - the partner companies has been largely sponsored by the Chinese government and the Memorandum of Understanding signed in the presence and blessing of the authorities of the two countries just a few months ago. "
What will it take to go from the auspices of the results? "Years ago I would have said that it would take at least a decade to open the market now - assumed Baielli - the timing was almost halved. I would say six years. "
There is a certain satisfaction, by Nerviano Medical Sciences, in having mollifying the deal: "Certainly our research assets will be made available to a developing country to obtain resources to help them continue the research and investment. All resources that otherwise would not have been possible to find. "
Naturally you must still sign the final contract, as agreed in the pre-contract welding. But this aspect falls outside the usual contractual dynamics typical of Chinese culture.
Read the article Original
0 comments:
Post a Comment